A review of hepatitis c virus (HCV) and the current management of genotype 1 chronic HCV infection

Authors

  • Ipalibo Simpson Wokoma Department of Internal Medicine, University of Port Harcourt, Port Harcourt
  • Richard Ishmael Oko-Jaja Department of Internal Medicine, University of Port Harcourt, Port Harcourt

Keywords:

Hepatitis C genotype 1, Pegylated Interferon (Peg IFN), Protease inhibitors (PI), Telaprevir (TVR), Boceprevir (BOC), Ribavirin(RBV).

Abstract

Background: Chronic Hepatitis C virus (HCV) is the primary cause of cirrhosis, hepatocellular carcinoma (HCC), and end- stage liver disease. The addition of protease inhibitor with peginterferon alfa and ribavirin (triple therapy) for genotype 1 infected patients, are the current standard of care.

Method: Data was sourced from available journals and internet based search using pubmed, medline and google search.

Results: successful Treatment of Genotype 1 HCV infected patients with protease inhibitor based triple therapy has improved sustained virologic response (SVR) rates and treatment induced clearance of HCV infection.

Conclusion: significant progress in the management of chronic hepatitis C genotype 1 with the introduction of protease inhibitor (PI) in 2011 with peginterferon and ribavirin has optimized sustained virologic response (SVR).

References

Lauer GM, walker BD. Hepatitis C virus infection. N Eng1 J Med 2001; 345: 41-52.

Kanwai F, Hoang T, kramer JR. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011; 140:1182-1188.

Backus Li, Boothroyd DB, Phillips BR. A sustained virologic response reduces risk of all-cause mortality is patients with hepatitics C. clin gastroerterol Hepatol 2011; 9:509 – 516.

Morgan TR, Ghany MG, Kim HY. Outcome of sustained virnogical responders with histologically advanced chronic hepatitic C. Hepatrology 2010; 52:833-44.

George SL, Bacon BR, Brunt EM, Clinical virologic,histologic,andbiochemicaloutcomes after successful HCV therapy: a 5 year follow up of 150 patients. Hepatology 2009; 49:729-38.

Poordad F, McCone J Jr, Bacon BR, Brumo S, Manns MP, Sulkowski MS, Jacobson. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-1206.

Jacobson IM, McHutchison JG, Dusheiko G. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-16.

Zeuzem S, Androne, P, Pol S. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-2428.

World Health Organization. Hepatitis C. WHO fact sheet No. 164 what year.

Alter MG, Kruszon-Moran D, Naina OV. the prevalence of hepatitis C virus infection in the United States. 1988 through 1994. N Eng1 J Med 1999; 341; 556 – 562.

Centre for disease control and prevent. Recommendationforpreventionandcontrol of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 1998; 47 (No. RR-19): 1-39.

Olubuyide I O, Aliyu MB, Olaleye OA. Hepatitis B and C virus and hepatecellular carcinoma. Trans R Soc Trop Med Hyg 1997; 9;38-41.

Obienu O, Nwokediuko S, Malu A, Lesi OA GastroenterolResPract2011;2011:939673.

Multimer Dj. Olomu A, Skidmore S viral hepatitis in Nigeria sickle cell disease and blood donors. QJM 1994; 87:407-411.

Olokoba AB, Acama LA, Gashau W, Salawi FK. Trop Doct. 2011 Jul; 41(3): 146-7

Nelson PK, Mathers BM, Cowie B. Global Epidemiology of hepatitis B and hepatitis C in people who inject drugs: result of systematic reviews. Lancet 2011; 378:571-16.

William I. Epidemiology of hepatitis C in the United States. Am J Med 1989; 107:2S-9S.

NIHconsensusprogram.NationalInstitutesofHealthConsensusdevelopment conference panel statement: management of hepatitis C. Hepatology 1997; 26:2S-10S.

Poynard T, Bedossa P, Opolon P. Natural historyofliverfibrosisMETAVIR,CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-32.

The VA Hepatitis C Resources Center program and National Hepatitis C program office VHA. Management of Psychiatric and substance use disorders in patients with Hepatitis C: A Reference for hepatitis C care providers 2005, pp 1-36.

HOSB,GroesslE,DollarhideA.Management of chronic hepatitis C in vaterans: the potential of integrated care model. Am J Gastroenterol 2008:103; 1810-23.

Dienstag JL. The role of liver biopsy in chronic hepatitis C. hepatology 2002; 36: S152 – 60.

McHutchison JG, lawits EJ, Shiffman ML, Muir AJ, Galler GW, Mccone J, et al. peginterferon alfa-2b or alfa 2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361:580-593.

Manns MP, McHutchison JG, Gordon SC. Peginterferonalfa-2bplusribavirincompared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001;358:958-965.

Jacobson IM, McHutchison JG, Dusheiko GM,etal.TelaprevirforpreviouslyuntreatedchronichepatitisCvirusinfection. N Engl J Med. 2011;364:2405 – 2416.

Bacon Br, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-1217.

FriedMW, ShiffmanML, Reddy KR. Peginterferon alfa-21 plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.

Sulkowksi MS, Wasserman R, Brooks L, Ball L, Gish R. Changes in hemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat 2004; 11(3): 243 – 250.

Downloads

Published

2015-12-22

How to Cite

Wokoma, I. S., & Oko-Jaja, R. I. (2015). A review of hepatitis c virus (HCV) and the current management of genotype 1 chronic HCV infection. The Nigerian Health Journal, 12(4), 90. Retrieved from https://tnhjph.com/index.php/tnhj/article/view/142

Similar Articles

1 2 > >> 

You may also start an advanced similarity search for this article.